Ligand Pharmaceuticals; WKN: 895777 (LGND) - 500 Beiträge pro Seite

[winetrader]

Ich denke langsam muß man einen thread für diese Aktie beginnen.
Nachfolgend werde ich eine gestrige news posten, die einen ersten Überblick gibt.
Denn Ligand Pharmaceuticals gehört zu den wenigen Unternehmen im Biotechbereich, die bereits auch Produkte am Markt haben.


Monday November 13, 7:09 pm Eastern Time
Press Release
Ligand Reports Third Quarter 2000 Results: Product Sales Up 129% and Net Loss per Share Down 33%
Ligand Reports Positive Data in Lung Cancer Patients Taking
Targretin Capsules, Receives Milestones On Advances in Collaborative

Product Pipeline

SAN DIEGO--(BW HealthWire)--Nov. 13, 2000--Ligand Pharmaceuticals Incorporated (Nasdaq:LGND - news) today reported revenues of $12.1 million in the third quarter ended September 30, 2000, compared to $9.8 million in the third quarter of 1999, a 24% increase. Net loss was $14.9 million (basic and diluted net loss of $0.26 per share) in the third quarter 2000, a decrease of $3.4 million or 18% (or 33% per share) from the net loss of $18.3 million ($0.39 per share) in the third quarter 1999.

For the nine months ended September 30, 2000, revenues were $34.5 million compared to $28.5 million for the nine months ended September 30, 1999, a 21% increase. In the same period, net loss was $46.3 million ($0.84 per share), a decrease of $5.5 million or 11% (or 24% per share) from the $51.9 million ($1.11 per share) net loss in the nine months ended September 30, 1999.

In announcing the results, Paul V. Maier, Ligand Senior Vice President and Chief Financial Officer, said, ``We are pleased with the acceleration of growth of product revenues in the third quarter 2000 and with the positive new clinical data for Targretin capsules with prospects to expand current marketed indications. Net product sales of $6.5 million in the third quarter 2000, up 32% over second quarter 2000, reflect a doubling of sales of Targretin capsules to $2.4 million from $1.2 million in the second quarter 2000, the August launch of our most recently approved product, Targretin® gel, with $0.7 million in sales, and a stable sales pattern for ONTAK®, with $2.9 million in sales, each within the range of our expectations.

``We continue to develop our marketed products in additional larger-market indications, including non-small cell lung cancer (Targretin capsules), breast cancer (Targretin capsules) and non-Hodgkin`s lymphoma (ONTAK). In August, we reported results of clinical trials of Targretin capsules in NSCLC, suggesting that Targretin capsules may extend the survival of these critically ill chemotherapy-treated patients. Similar patterns are emerging from other studies we have conducted in head and neck cancer, and kidney cancer. After discussions with the FDA scheduled for later this quarter, we anticipate initiating pivotal Phase III trials of Targretin capsules in NSCLC in 2001.

``We also enhanced the value of our corporate partner product pipeline and our royalty-based business during the third quarter 2000,`` Maier continued. ``In September, we recorded milestone payments from Pfizer for its launch of Phase III trials of lasofoxifene for the treatment of women with post menopausal osteoporosis and from Lilly based on the advancement of major new compounds to treat diabetes and cardiovascular disease.

``We continue to reduce net losses and cash burn by increasing revenues and maintaining tight controls on our expenses. During the third quarter and the first nine months 2000 compared to the same periods in the prior year, increased investments in new product launches were largely offset by declines in R&D and G&A expenses.``

Third Quarter and Nine Month 2000 Results

Product sales of $6.5 million in the third quarter ended September 30, 2000, grew 129% compared to sales for the same period in 1999 and 32% compared to the second quarter of 2000. The increase in third quarter sales reflected launch of Targretin capsules in late January 2000 and Targretin gel in August 2000. For the first nine months of 2000, product sales were $16.2 million compared to $9.1 million for the same period in 1999.
Sales of Targretin capsules doubled to $2.4 million during third quarter over second quarter and further accelerated its new patient prescription adoption rate with nearly 250 new patient prescriptions in September alone. Refill prescriptions grew more than 67% during the third quarter as existing patients continued their Targretin therapy. Physicians continue to explore Targretin dosage in both monotherapy and combination regimens and in applications beyond CTCL.
Targretin gel launch was initiated during the third quarter and built solidly upon the Targretin capsule franchise with sales of $0.7 million and nearly 150 new patient prescriptions in September alone, its first full month of sales. The combined sales of Targretin capsules and gel of $3.1 million exceeded that of ONTAK for the first time in third quarter.
ONTAK sales were largely stable during the third quarter but began to show signs of return to growth by the end of the quarter as physicians began to clarify the relevant roles of both ONTAK and Targretin in their patient populations. During the quarter, some physicians also began using combinations of ONTAK and Targretin in CTCL. These trends should facilitate a return to growth of ONTAK sales in fourth quarter going forward.
Collaborative research and development and other milestone revenues were $5.6 million in the third quarter 2000 versus $6.3 million in the third quarter 1999, and $18.3 million in the first nine months of 2000 versus $17.5 million in the first nine months of 1999. Milestone and other revenues are expected to accelerate during fourth quarter.
Research and development expenses were $13.2 million in the third quarter 2000, a decrease of $2.5 million, or 16%, from $15.7 million in the third quarter 1999. In the first nine months of 2000, R&D expenses were $38.5 million versus $44.8 million in the prior year, a decrease of $6.3 million or 14%. The decreases reflect a reduction in expenses for research and development associated with the completion of the NDA for Targretin capsules in June 1999 and for Targretin gel in December 1999.
Selling, general and administrative expenses were $8.6 million in the third quarter 2000 compared to $6.0 million in the third quarter 1999, and $25.9 million in the first nine months of 2000 versus $20.1 million in the same period of 1999. The increases are attributable to expansion of sales and marketing activities for Targretin capsules and Targretin gel launches and the continued marketing of ONTAK and Panretin gel.
Loss from operations declined $3.2 million or 21% from $15.1 million in the third quarter 1999 to $12.0 million in the third quarter 2000 and declined $8.3 million or 19% from $44.6 million in the first nine months of 1999 to $36.2 million in the first nine months of 2000.
As of September 30, 2000, Ligand had cash, cash equivalents, short-term investments and restricted cash of $33.0 million versus $49.2 million as of December 31, 1999. Under the terms of our strategic alliance with Elan, an additional $10 million in zero coupon convertible notes are available to Ligand through December 31, 2000.
Web Cast Conference Call

Ligand Pharmaceuticals will host a live web cast, open to all interested parties, of a conference call during which David E. Robinson, Ligand Chairman, President and CEO, and Paul V. Maier, Senior Vice President and Chief Financial Officer, will discuss earnings for third quarter and the first nine months of 2000. The web cast will be available at http://www.streetevents.com and at http://www.ligand.com (Investor/Public Relations page) on Tuesday, November 14, 2000, at 8:30 a.m. Eastern Standard Time.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, skin diseases, and men`s and women`s hormone-related diseases, as well as osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. Ligand`s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to Intracellular Receptors (IRs) and Signal Transducers and Activators of Transcription (STATs).

This news release may contain certain forward-looking statements by Ligand which involve risks and uncertainties and reflect Ligand`s judgement as of the date of this release. Actual events or results may differ from Ligand`s expectations. There can be no assurance that results of subsequent clinical studies of Targretin capsules, ONTAK or any other Ligand or corporate partner product will confirm earlier results, will be submitted to or approved by the FDA in a timely fashion or at all, or, if approved, such product will be accepted by physicians for prescribing, by patients for use and by insurance companies/agencies for reimbursement. Additional information concerning these and other risk factors affecting Ligand`s business can be found in prior press releases as well as in Ligand`s public periodic filings with the Securities and Exchange Commission, available via Ligand`s website at http://www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

Full prescribing information for Ligand`s products may be obtained in the U.S. from Ligand Professional Services by calling toll free 800-964-5836 or on Ligand`s web site at http://www.ligand.com.

Ligand Pharmaceuticals` releases are available on the World Wide Web at www.businesswire.com/cnn/lgnd.htm.



LIGAND PHARMACEUTICALS INCORPORATED
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)

Three Months Ended Nine Months Ended
Sept. 30, Sept. 30,
------------------ -------------------
2000 1999 2000 1999
---- ---- ---- ----
Revenues:
Product sales $ 6,477 $ 2,830 $ 16,234 $ 9,127
Collaborative
research and
development
and other
revenues 5,593 6,279 18,277 17,456
Contract
manufacturing -- 656 -- 1,884
-------- -------- -------- --------
Total revenues 12,070 9,765 34,511 28,467
-------- -------- -------- --------

Operating costs
and expenses:
Cost of
products sold 2,238 1,027 6,328 2,997
Contract
manufacturing -- 2,136 -- 5,180
Research and
development 13,229 15,717 38,480 44,799
Selling, general
and administrative 8,560 6,015 25,938 20,056
-------- -------- -------- --------
Total operating
costs and
expenses 24,027 24,895 70,746 73,032
-------- -------- -------- --------

Loss from
operations (11,957) (15,130) (36,235) (44,565)

Interest income 645 623 2,072 1,894
Interest expense (3,221) (3,551) (9,885) (8,942)
Debt conversion expense -- -- (2,025) --
Other, net (393) (248) (267) (245)
-------- -------- -------- --------
Net loss $(14,926) $(18,306) $(46,340) $(51,858)
======== ======== ======== ========

Basic and
diluted net
loss per share $ (0.26) $ (0.39) $ (0.84) $ (1.11)
======== ======== ======== ========
Shares used in
computing net
loss per share 56,605 47,476 55,341 46,580
======== ======== ======== ========


CONSOLIDATED BALANCE SHEETS
(in thousands)

Sept. 30, Dec. 31,
2000 1999
-------------- --------
Assets
Current assets:
Cash, cash equivalents and
short-term investments $ 31,562 $ 47,155
Other current assets 12,474 9,524
--------- ---------
Total current assets 44,036 56,679
Restricted investments 1,434 2,011
Property and equipment, net 11,784 20,542
Acquired technology, net 41,685 38,969
Other assets 16,072 16,444
--------- ---------
$ 115,011 $ 134,645
========= =========
Liabilities and Stockholders`
Deficit
Current liabilities $ 22,455 $ 20,701
Accrued acquisition obligation 2,700 2,900
Long-term portion of equipment
financing obligations 5,305 6,907
Convertible debentures and notes 114,891 129,727
Stockholders` deficit (30,340) (25,590)
--------- ---------
$ 115,011 $ 134,645
========= =========


--------------------------------------------------------------------------------

[JoeUp]

winetrader,

den Thread gibt es. Gib einfach LIGAND ein

JoeUp

[winetrader]

Sorry JoeUp,

hatte vermutlich den kompletten Namen von LGND eingegeben und somit den anderen thread nicht angezeigt bekommen.
An alle nachfolgenden Interessenten:
Gebt NUR "Ligand" ein!

winetrader